Tharimmune Stock (NASDAQ:THAR)


FinancialsChart

Previous Close

$2.10

52W Range

$1.83 - $8.41

50D Avg

$2.29

200D Avg

$3.72

Market Cap

$3.08M

Avg Vol (3M)

$1.26M

Beta

1.45

Div Yield

-

THAR Company Profile


Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Jan 12, 2022

Website

THAR Performance


THAR Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-9.46M$-6.88M$-3.21M
Net Income$-9.32M$-8.47M$-2.21M
EBITDA$-9.30M$-6.88M$-1.38M
Basic EPS$-7.14$-18.72$-4.85
Diluted EPS$-7.14$-18.72$-4.85

Fiscal year ends in Dec 23 | Currency in USD